The short answer
TRIUMPH-1 (NCT05929066) reported topline results on 21 May 2026. Across 2,339 randomised adults, mean weight reduction at 80 weeks was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, against 2.2% on placebo. A 104-week extension reported 30.3% mean reduction on 12 mg among participants with baseline BMI of 35 or above.
Key facts
- Trial
- TRIUMPH-1 (NCT05929066)
- Topline reported
- 21 May 2026
- Randomised
- 2,339 adults
- Primary duration
- 80 weeks
- Extension
- 104 weeks, 532 participants
- Best mean reduction
- 28.3% at 80 wks (12 mg)
- Extension result
- 30.3% at 104 wks (12 mg, BMI ≥35)
- Regulatory status
- Still investigational (no authorisation anywhere)
Trial design
TRIUMPH-1 is the pivotal obesity study in Eli Lilly's Phase 3 programme for retatrutide, registered as NCT05929066. It randomised 2,339 adults across three active dose arms and placebo, with a primary analysis at 80 weeks and a continuing extension to 104 weeks in a subset of 532 participants. The programme as a whole has enrolled more than 5,800 people.
Weight reduction by dose arm
Mean reductions at 80 weeks were 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, compared with 2.2% on placebo. The dose-response relationship is clean and monotonic across the three arms, which is one of the reasons the result was treated as robust rather than a single striking headline number.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Threshold analyses
On the 12 mg arm, 62.5% of participants achieved at least 25% reduction, 45.3% achieved at least 30%, and 27.2% achieved at least 35%. Additionally 65.3% reached a BMI below 30. The 30% threshold attracted the most comment because reductions of that magnitude had previously been associated with bariatric surgery rather than pharmacotherapy.
- ≥25% reduction, 62.5% of participants (12 mg)
- ≥30% reduction, 45.3% of participants (12 mg)
- ≥35% reduction, 27.2% of participants (12 mg)
- BMI below 30 achieved, 65.3% of participants (12 mg)
Adverse events
The safety profile was consistent with the incretin class and dominated by gastrointestinal events. Nausea was reported by 42.4% on 12 mg against 14.8% on placebo, and diarrhoea by 32.0% against 13.5%. Discontinuation due to adverse events occurred in 11.3% of the 12 mg arm against 4.9% on placebo. A meaningful figure, and one that is frequently omitted when these results are summarised.
What it does not mean
Retatrutide remains investigational. It holds no marketing authorisation from the MHRA, the EMA or the FDA, and a positive pivotal trial does not change that. Lilly has indicated it intends to file with the FDA in the first quarter of 2027. The dose arms above describe a registered clinical trial conducted under medical supervision; they are reported here as trial facts and are not handling guidance for anything.
Quick reference
| Arm | Mean reduction (80 wks) | Absolute |
|---|---|---|
| Placebo | 2.2% | 5.5 lbs |
| 4 mg | 19.0% | 47.2 lbs |
| 9 mg | 25.9% | 64.4 lbs |
| 12 mg | 28.3% | 70.3 lbs |
Frequently asked questions
Is retatrutide approved after TRIUMPH-1?
No. It remains investigational worldwide. Lilly has signalled an FDA filing in Q1 2027, and filing is the start of a review, not the end of one.
How does 28.3% compare with tirzepatide?
It is higher than the reductions reported in tirzepatide's pivotal obesity trials, which is the reason TRIUMPH-1 drew the attention it did.
Why does the 104-week figure only cover BMI ≥35?
The 30.3% figure comes from the extension subset with that baseline characteristic, so it is not directly comparable with the full-population 80-week result.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Retatrutide TRIUMPH-2 and TRIUMPH-3: What They AddedTRIUMPH-2 and TRIUMPH-3 reported in July 2026, covering type 2 diabetes and cardiovascular disease. Results, context and the remaining readouts.
- Where the MHRA Draws the Line on Research PeptidesUK law regulates claims and intended use, not the compound. What makes a product an unlicensed medicine, and how the MHRA has enforced that line in 2026.
- Counterfeit GLP-1 Products: The 2026 UK PictureMHRA seizures of counterfeit GLP-1 pens, a 265% rise in US poison-centre exposures, and why certificate-of-analysis verification is the only practical defence.
- Orforglipron in the UK: Access, Cost and the NHS QuestionFoundayo is available in the UK on private prescription only, reported at roughly £99-£179 a month. NHS funding awaits NICE guidance expected 18 November 2026.
- Orforglipron: Reported Side Effects and TolerabilityNausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain are most commonly reported. Why the profile is a GLP-1 class effect, not a surprise.